Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors
Immunome, Inc. (IMNM)
Company Research
Source: Business Wire
Registrational trial met primary endpoint, with varegacestat significantly improving progression-free survival vs. placebo (hazard ratio = 0.16, pTrial also met all key secondary endpoints, with varegacestat delivering an objective response rate of 56%Varegacestat was generally well tolerated with a manageable safety profileNew Drug Application submission to U.S. FDA planned for Q2 2026Company to host conference call today at 8:30 a.m. ET BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced positive topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), in patients with progressing desmoid tumors.The trial met its primary endpoint of improving progression-free survival, demonstrating a statistically significant and clinically meaningful improvement vs. pla
Show less
Read more
Impact Snapshot
Event Time:
IMNM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMNM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMNM alerts
High impacting Immunome, Inc. news events
Weekly update
A roundup of the hottest topics
IMNM
News
- Why Immunome Stock Surged Today [Yahoo! Finance]Yahoo! Finance
- Immunome (NASDAQ:IMNM) was given a new $40.00 price target on by analysts at Leerink Partners.MarketBeat
- Immunome Announces Proposed Public Offering of Common Stock [Yahoo! Finance]Yahoo! Finance
- Immunome Announces Proposed Public Offering of Common StockBusiness Wire
- Stocks making the biggest moves midday: Zillow, KLA, iRobot, Immunome & more [CNBC]CNBC
IMNM
Earnings
- 8/6/25 - Beat
IMNM
Sec Filings
- 12/15/25 - Form 424B5
- 12/15/25 - Form 8-K
- 11/7/25 - Form SCHEDULE
- IMNM's page on the SEC website